Bright Minds Biosciences Inc.
DRUGHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Bright Minds Biosciences Inc. (DRUG) is listed under Biotechnology. At a $639.4M market cap, Bright Minds Biosciences Inc. ranks as a small-cap company within healthcare. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Market Cap
$639.4M
Beta
-0.11
P/E (TTM)
—
P/E (Fwd)
-11.05
EPS (TTM)
$-2.05
EPS (Fwd)
$-5.90
ROE
-13.6%
ROA
-13.5%
Cash
$307.8M
Total Debt
$65,589
Free CF
-$18.8M
52W Change
54.5%
Annual Financials
Cash vs Debt
Where DRUG stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, DRUG finished 2.20% above its 150-day moving average ($77.78) and 2.78% above its 200-day moving average ($77.34). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DRUG overbought or oversold?
At the August 26, 2026 close, DRUG's RSI(14) was 49.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $307.8M in cash comfortably exceeding the $66K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$18.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -13.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With a beta below 0.7, Bright Minds Biosciences Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, DRUG has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bright Minds Biosciences Inc. and its sector.